Fugazza Alessandro, Andreozzi Marta, Binda Cecilia, Lisotti Andrea, Tarantino Ilaria, Vila Juan J, Robles Medranda Carlos, Amato Arnaldo, Larghi Alberto, Perez Cuadrado Robles Enrique, Aragona Giovanni, Di Matteo Francesco, Badas Roberta, Hassan Cesare, Barbera Carmelo, Mangiavillano Benedetto, Crinò Stefano, Colombo Matteo, Fabbri Carlo, Fusaroli Pietro, Facciorusso Antonio, Anderloni Andrea, Spadaccini Marco, Repici Alessandro
Division of Gastroenterology and Digestive Endoscopy, Humanitas Research Hospital-IRCCS, 20089 Rozzano, Italy.
Gastroenterology and Digestive Endoscopy Unit, Forlì-Cesena Hospitals, AUSL Romagna, 47121 Forlì, Italy.
Cancers (Basel). 2024 Oct 2;16(19):3375. doi: 10.3390/cancers16193375.
EUS-guided gastroenterostomy (EUS-GE) is a novel and effective procedure for the management of malignant gastric outlet obstruction (GOO) with more durable results when compared to enteral stenting (ES). However, data comparing EUS-GE to ES in patients already treated with EUS-guided choledocoduodenostomy (EUS-CDS) for distal malignant biliary obstruction (DMBO) are lacking. We aimed to compare outcomes of EUS-GE and ES for the palliation of GOO in this specific population of patients.
A multicenter, retrospective analysis of patients with DMBO treated by EUS-CDS and subsequent GOO treated by EUS-GE or ES from 2016 to 2021 was conducted. Primary outcomes were overall AEs rate and dysfunction of the EUS-CDS after GOO treatment. Secondary outcomes included clinical success, technical success, procedure duration, length of hospital stay and relapse of GOO symptoms.
A total of 77 consecutive patients were included in the study: 25 patients underwent EUS-GE and 52 underwent ES. AEs rate and patency outcomes of the EUS-CDS after GOO treatment were comparable between the two groups (12.5% vs. 17.3%; = 0.74). No recurrence of GOO symptoms was registered in the EUS-GE group while 11.5% of ES patients had symptoms recurrence, even if not statistically significant ( = 0.16), after a mean follow-up period of 63.5 days.
EUS-GE and ES are both effective and safe for the palliation of GOO in patients already treated by EUS-CDS for DMBO with no difference in the biliary stent dysfunction rate and overall AEs. EUS-GE is associated with less recurrence of GOO symptoms.
内镜超声引导下胃造口术(EUS-GE)是治疗恶性胃出口梗阻(GOO)的一种新型有效方法,与肠内支架置入术(ES)相比,其效果更持久。然而,目前缺乏在已接受内镜超声引导下胆总管十二指肠吻合术(EUS-CDS)治疗远端恶性胆管梗阻(DMBO)的患者中,比较EUS-GE与ES的相关数据。我们旨在比较EUS-GE和ES在这一特定患者群体中缓解GOO的疗效。
对2016年至2021年期间接受EUS-CDS治疗DMBO并随后接受EUS-GE或ES治疗GOO的患者进行多中心回顾性分析。主要结局是总体不良事件发生率和GOO治疗后EUS-CDS的功能障碍。次要结局包括临床成功率、技术成功率、手术持续时间、住院时间和GOO症状复发情况。
本研究共纳入77例连续患者:25例行EUS-GE,52例行ES。两组GOO治疗后EUS-CDS的不良事件发生率和通畅情况相当(12.5%对17.3%;P = 0.74)。EUS-GE组未出现GOO症状复发,而ES组11.5%的患者出现症状复发,平均随访63.5天后,差异无统计学意义(P = 0.16)。
对于已接受EUS-CDS治疗DMBO的患者,EUS-GE和ES在缓解GOO方面均有效且安全,胆管支架功能障碍率和总体不良事件无差异。EUS-GE与GOO症状复发较少相关。